Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Change in Account Payables (2021 - 2025)

Senti Biosciences has reported Change in Account Payables over the past 5 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Change in Account Payables at $1.2 million for Q4 2025, down 5.33% from a year ago — trailing twelve months through Dec 2025 was $1.7 million (up 118.7% YoY), and the annual figure for FY2025 was $1.7 million, up 118.7%.
  • Change in Account Payables for Q4 2025 was $1.2 million at Senti Biosciences, up from $750000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for SNTI hit a ceiling of $1.2 million in Q4 2024 and a floor of -$2.3 million in Q4 2021.
  • Median Change in Account Payables over the past 5 years was $2299.0 (2021), compared with a mean of $5381.3.
  • Peak annual rise in Change in Account Payables hit 8718.97% in 2022, while the deepest fall reached 585814.29% in 2022.
  • Senti Biosciences' Change in Account Payables stood at -$2.3 million in 2021, then soared by 103.99% to $93000.0 in 2022, then plummeted by 911.83% to -$755000.0 in 2023, then skyrocketed by 264.11% to $1.2 million in 2024, then decreased by 5.33% to $1.2 million in 2025.
  • The last three reported values for Change in Account Payables were $1.2 million (Q4 2025), $750000.0 (Q3 2025), and -$537000.0 (Q2 2025) per Business Quant data.